Sanara MedTech Inc. SMTI
35.06
(0.04)
(0.11%)
as of 25 Sep
- Market cap
- $322.5M
- P/E
- 0.0×
Follow SMTI
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.69 | 1.95 | 1.39 | 1.86 | |
P/FCF ratio |
0.00 | 92.62 | 44.97 | 45.85 | |
P/Operating CF |
126.06 | 51.04 | (60.67) | 100.25 | |
P/B ratio |
44.68 | 33.96 | 21.31 | 25.76 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.00 | 2.25 | 1.70 | 2.15 | |
EV/EBITDA |
18.74 | 20.09 | 14.28 | 20.33 | |
EV/Operating CF |
80.94 | 34.14 | 28.98 | 41.50 | |
EV/FCF |
(368.45) | 106.57 | 55.06 | 53.03 | |
Quick Ratio |
1.56 | 1.53 | 1.99 | 2.24 | |
Current Ratio |
1.80 | 1.80 | 2.28 | 2.58 | |
Net Debt/EBITDA |
7.44 | 16.40 | 9.87 | 12.56 | |
Debt/Assets |
63.43% | 63.02% | 66.73% | 67.22% | |
Debt/Equity |
7.34 | 7.75 | 6.59 | 5.86 | |
Asset Turnover |
1.28 | 1.28 | 1.30 | 1.31 | |
Operating CF/Net income |
(0.07) | (2.45) | (5.37) | (4.50) | |
Capex/Depreciation |
(0.95) | (0.11) | (0.07) | (0.01) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
3.91% | 7.39% | 2.73% | 4.10% | |
Selling, General and Administrative Expense of Revenue |
75.48% | 72.88% | 78.71% | 80.33% | |
Intangible Assets out of Total Assets |
0.35 | 0.30 | 0.31 | 0.30 | |
Share Based Compensation of Revenue |
4.68% | 4.29% | 3.70% | 5.32% | |
Graham Net Nets |
(0.12) | (0.17) | (0.21) | (0.14) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(13.68%) | (18.63%) | (22.64%) | (15.73%) | |
Free Cash Flow Yield |
(0.30%) | 1.08% | 2.22% | 2.18% | |
Revenue per Share |
3.05 | 3.19 | 3.19 | 3.25 | |
Operating CF per Share |
0.25 | 0.46 | (0.28) | 0.24 | |
Capex per Share |
(0.12) | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.13 | 0.45 | (0.29) | 0.23 | |
Cash per Share |
1.73 | 1.92 | 1.56 | 1.78 | |
Shareholders Equity per Share |
0.71 | 0.69 | 0.81 | 0.92 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.71 | 0.69 | 0.81 | 0.92 | |
Free Cash Flow |
1.12 | 3.86 | (2.51) | 2.03 | |
Working Capital |
13.87 | 14.92 | 17.50 | 19.71 | |
Capital Expenditures |
(1.06) | (0.08) | (0.04) | (0.01) | |
Net Current Asset Value |
(33.72) | (33.47) | (31.06) | (29.01) | |
EV/EBIT |
27.39 | 31.72 | 20.07 | 28.07 | |
Capex to Sales |
0.04 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(115.48%) | (5.84%) | 1.65% | (1.61%) | |
Price to Operating Income |
24.61 | 27.56 | 16.39 | 24.27 | |
| Other line items | |||||
Average Receivables |
11.60 | 12.22 | 12.76 | 12.29 | |
Average Payables |
1.31 | 1.93 | 1.53 | 1.45 | |
Average Inventory |
3.20 | 3.35 | 3.14 | 3.49 | |
Average Assets |
79.82 | 80.52 | 82.83 | 83.96 | |
Average Common Equity |
22.80 | 22.42 | 21.84 | 21.66 |
Columns are period end dates